Novartis AG ADR (NYSE: NVS) has a price-to-earnings ratio that is above its average at 13.05x. The stock has a 36-month beta value of 0.55. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for NVS is 1.96B, and at present, short sellers hold a 0.22% of that float. On April 17, 2024, the average trading volume of NVS was 1.48M shares.
NVS) stock’s latest price update
Novartis AG ADR (NYSE: NVS) has experienced a decline in its stock price by -1.28 compared to its previous closing price of 94.41. However, the company has seen a fall of -2.72% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-16 that Novartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for the treatment of immunoglobulin A nephropathy, a heterogeneous, progressive, rare kidney disease.
NVS’s Market Performance
Novartis AG ADR (NVS) has experienced a -2.72% fall in stock performance for the past week, with a -4.18% drop in the past month, and a -13.46% drop in the past quarter. The volatility ratio for the week is 1.07%, and the volatility levels for the past 30 days are at 0.93% for NVS. The simple moving average for the last 20 days is -2.38% for NVS’s stock, with a simple moving average of -4.95% for the last 200 days.
Analysts’ Opinion of NVS
Many brokerage firms have already submitted their reports for NVS stocks, with BMO Capital Markets repeating the rating for NVS by listing it as a “Market Perform.” The predicted price for NVS in the upcoming period, according to BMO Capital Markets is $114 based on the research report published on February 23, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see NVS reach a price target of $114. The rating they have provided for NVS stocks is “Equal-Weight” according to the report published on January 23rd, 2024.
NVS Trading at -5.88% from the 50-Day Moving Average
After a stumble in the market that brought NVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.32% of loss for the given period.
Volatility was left at 0.93%, however, over the last 30 days, the volatility rate increased by 1.07%, as shares sank -2.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.14% lower at present.
During the last 5 trading sessions, NVS fell by -2.72%, which changed the moving average for the period of 200-days by -6.20% in comparison to the 20-day moving average, which settled at $95.34. In addition, Novartis AG ADR saw -7.70% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NVS
Current profitability levels for the company are sitting at:
- 0.2 for the present operating margin
- 0.72 for the gross margin
The net margin for Novartis AG ADR stands at 0.29. The total capital return value is set at 0.14. Equity return is now at value 16.52, with 7.76 for asset returns.
Based on Novartis AG ADR (NVS), the company’s capital structure generated 0.36 points at debt to capital in total, while cash flow to debt ratio is standing at 0.55. The debt to equity ratio resting at 0.56. The interest coverage ratio of the stock is 11.58.
Currently, EBITDA for the company is 18.47 billion with net debt to EBITDA at 0.69. When we switch over and look at the enterprise to sales, we see a ratio of 3.94. The receivables turnover for the company is 5.44for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.16.
Conclusion
To sum up, Novartis AG ADR (NVS) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
